Abstract
Nonalcoholic fatty liver disease is increasing with the rise in obesity and metabolic risk factors like diabetes mellitus. Type 2 diabetics are highly prone to deranged liver function test. Increase in serum aminotransferases level is an indicator of hepatocellular injury. The aim of this study is to correlate serum aminotransferases level with anthropometric measurements, diabetic retinopathy and types of treatment received in diabetics. A total of 236 patients (142 females) of age more than 40 years with type 2 diabetes attending Nepal Medical College and Teaching Hospital between February 2016 and January 2017 were included in this cross-sectional observational study. Blood samples were sent for fasting blood sugar, HbA1c and serum aminotransferases tests. Body mass index and waist hip ratio were measured as per standard protocol. Fundoscopy was done in all patients. Pearson and independent t-test were applied to see the correlation between the variables. The mean HbA1c was 8.01± 2.08. In the sub group analysis, serum aminotransferases level was significantly high in patients with poor glycemic control, higher body mass index and waist hip ratio (p value < 0.001). Patients with diabetic retinopathy also had higher serum aminotransferases level (p value < 0.001). Pearson correlation between HbA1c with serum alanine aminotransferases level was significant (r=0.76, n=5, p value < 0.001).
Highlights
Diabetes mellitus is one of the major noncommunicable diseases and the prevalence is rising globally.[1]
Nonalcoholic Fatty Liver (NAFL) leads to nonalcoholic steatohepatitis (NASH), a progressive fibrotic disease, which can result in cirrhosis or liver related death.[6]
The insulin resistant state is marked by an increase in proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), which may contribute to hepatocellular injury.[13]
Summary
Diabetes mellitus is one of the major noncommunicable diseases and the prevalence is rising globally.[1] The prevalence of diabetes worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. Screening for NAFLD is not recommended for patients at increased risk
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
